Issue 8, 2017

Phospholipid-mimic oxaliplatin prodrug liposome for treatment of the metastatic triple negative breast cancer

Abstract

A phospholipid-mimic oxaliplatin prodrug (Oxalipid) was synthesized, which could self-assemble into a liposomal nanostructure with a drug loading ratio as high as 27 wt%. Compared to free oxaliplatin, the resulting Oxalipid liposome displayed elongated blood circulation, increased tumor accumulation and improved anticancer efficacy against the metastatic triple negative breast cancer (TNBC).

Graphical abstract: Phospholipid-mimic oxaliplatin prodrug liposome for treatment of the metastatic triple negative breast cancer

Supplementary files

Article information

Article type
Communication
Submitted
19 Jan 2017
Accepted
31 Mar 2017
First published
31 Mar 2017

Biomater. Sci., 2017,5, 1522-1525

Phospholipid-mimic oxaliplatin prodrug liposome for treatment of the metastatic triple negative breast cancer

B. Feng, F. Zhou, W. Lu, D. Wang, T. Wang, C. Luo, H. Wang, Y. Li and H. Yu, Biomater. Sci., 2017, 5, 1522 DOI: 10.1039/C7BM00058H

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements